Early Access — free while we kick the tires
EdgarHawk

Daniel Patrick O'Day

Chairman & CEO

Director Officer

Latest: Chair selling · June 2026

15 filings analyzed · 1 company · Latest 2026-06-02

Companies

Company Buys Sells Direction
GILEAD SCIENCES, INC. GILD 0 30 Net selling

Activity

June 2026
2026-06-02 GILEAD SCIENCES, INC. GILD
medium
Sell
15,000 shares
$1,971,847
Significance 5/10

O'Day (then-CEO) sells 15,000 GILD shares for $1,971,846.68 under pre-arranged 10b5-1 plan; stock down 13.9% in 90 days

Daniel Patrick O'Day, who was CEO at the time of filing, executed 3 separate sales totaling 15,000 shares for $1,971,846.68 on 2026-06-01 at prices ranging from $131.10 to $132.97. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, meaning the sales were scheduled and not discretionary. His post-transaction holding of 617.6K shares represents a -2.4% reduction from his prior 632.6K shares. The stock is currently trading at $127.57, down 18.9% from its 52-week high of $157.29 and down 13.9% over the past 90 days. His prior sales at GILD show mixed results: two April 2026 sales were followed by 30-day gains of 5.8% and 4.8%, while his March and February 2026 sales experienced 30-day declines ranging from -4.7% to -7.9%.

April 2026
2026-04-29 GILEAD SCIENCES, INC. GILD
medium
Sell
10,000 shares
$1,291,608
Significance 4/10

Gilead CEO O'Day sells ~$1.3M in stock as shares pull back from recent highs

CEO Daniel Patrick O'Day sold approximately $1.3 million in Gilead stock across two transactions, disposing of roughly 1.6% of his holdings in a single day. The timing is notable: the stock has pulled back noticeably from its recent highs and sits meaningfully below where it traded three months ago, suggesting O'Day is selling into weakness rather than at peak valuations. While Gilead remains a financially healthy, profitable company with strong revenue generation, this sale by the top executive during a down period could signal either portfolio rebalancing or a cautious view on near-term momentum. The modest reduction in his stake—less than 2% of total holdings—indicates this is not a wholesale liquidation, but it does represent a net reduction in his personal conviction at a time when the stock faces headwinds.

March 2026
2026-03-30 GILEAD SCIENCES, INC. GILD
medium
Sell
10,000 shares
$1,368,162
Significance 4/10

O'Day sells 10,000 GILD shares at $136.82; holds 642.6K post-trade. Stock down 12.5% from 52-week high.

O'Day Daniel Patrick, Chairman & CEO, sold 10,000 shares of Gilead on 2026-03-27 for $1,368,162.00 ($1.4M), reducing holdings by 1.5% to 642.6K shares. The sale occurred as GILD has declined 12.5% from its 52-week high of $155.80 and has fallen 8.5% over the trailing 30 days, though it remains up 10.7% over 90 days. His prior four sales at this ticker (all on 2026-02-27 and 2026-02-05) occurred weeks earlier and show mostly negative 30-day returns ranging from -7.9% to -4.0%, with one prior sale on 2026-01-28 posting +6.2%. Across his full cross-ticker open-market history, his 20 prior sales show an average 90-day return of +9.1% and a well-timed rate of 0.00%, indicating his historical sales have not preceded stock declines. The company maintains solid fundamentals: $7.8B quarterly revenue, $3.1B net income, and a 10.49 P/E ratio with a $169.3B market cap.

2026-03-02 GILEAD SCIENCES, INC. GILD
medium
Sell
10,000 shares
$1,447,859
Significance 4/10

Gilead CEO O'Day sells 10,000 shares at $144.04–$145.71 on 2026-02-27; retains 642,308 shares.

Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, executed 3 separate sales totaling 10,000 shares for $1,447,858.61 at blended average price $144.79. The current price is $150.03, meaning the CEO sold 2.5% below today's market level. O'Day retains 642,308 shares post-transaction, representing a 1.5% reduction in holdings. His same-ticker history at Gilead shows 5 recent sells (dating from 2025-12-29 to 2026-02-05) with measurable 30-day outcomes of +6.2%, +6.7%, +12.2%, and +11.9%, indicating stock appreciation following those sales. The stock is currently +5.7% over 30 days and +21.1% over 90 days, and sits -3.7% from its 52-week high of $155.80. This continued liquidation pattern—now four sales within roughly two months—warrants attention to whether the CEO's cadence reflects scheduled programmatic activity or discretionary reassessment of position size.

February 2026
2026-02-06 GILEAD SCIENCES, INC. GILD
medium
Sell
115,640 shares
$17,346,000
Significance 5/10

O'Day (Chairman & CEO) sold 115.6K shares of GILD at $150.00 for $17.3M; retains 613.9K shares.

Chairman Daniel Patrick O'Day sold 115,640 shares at $150.00 on 2026-02-05, representing a -15.9% reduction from his 729,552 pre-transaction holdings to 613,912 shares post-transaction. The sale price of $150.00 sits 1.6% below the current market price of $152.50 and aligns with the 52-week high, occurring amid strong recent momentum: the stock has gained 22.6% over 30 days and 28.3% over 90 days. O'Day's cross-ticker selling track record shows 17 prior sales with an average 90-day post-sale return of 7.7% (positive returns, indicating poorly timed exits), though his 90-day well-timed rate stands at 0.00%. At GILD specifically, prior sales on 2025-12-29 and 2026-01-23/28 have generated mixed results: the December sale showed a 30-day gain of 11.9%, while the most recent January sales remain unmeasurable. The company fundamentals remain solid (P/E 23.32, net income of $3.1B on $7.8B revenue, 6.0% annual growth), with market cap at $189.2B. This transaction warrants monitoring for potential patterns in executive liquidity decisions around peak valuations, though the CEO retains substantial holdings.

January 2026
2026-01-29 GILEAD SCIENCES, INC. GILD
medium
Sell
10,000 shares
$1,398,911
Significance 4/10

CEO O'Day sells 10,000 GILD shares for $1.4M; holds 556.7K post-sale amid +13.3% 30-day rally.

Daniel Patrick O'Day (Chairman & CEO) executed 2 separate sales totaling 10,000 shares for $1,398,911.15 on 2026-01-28, reducing his position by 1.8% to 556.698 shares. The transactions occurred at prices ($139.54 and $140.24) very close to the current market price of $139.55, near the 52-week high of $140.97. GILD has appreciated +13.3% over the prior 30 days and +16.5% over 90 days, placing the stock in the upper part of its 52-week range. O'Day's same-ticker history at GILD shows 5 prior sales dating back to October 2025, with mixed outcomes; his cross-ticker track record across all open-market sells shows a 90-day well-timed rate of 0.00%, indicating his prior sales have not historically preceded declines. The CEO retains a substantial 556.7K share position, consistent with continued material equity participation in the company.

2026-01-26 GILEAD SCIENCES, INC. GILD
medium
Sell
115,640 shares
$15,611,400
Significance 5/10

GILD CEO O'Day sells 115,640 shares ($15.6M) at $135.00; stock now at $137.78. Post-sale holdings: 566,698 shares (-16.9%).

O'Day Daniel Patrick sold 115,640 shares of Gilead Sciences at $135.00 on 2026-01-23, reducing his holdings by 16.9% to 566,698 shares post-transaction. The sale proceeds totaled $15,611,400.00. The current stock price of $137.78 is at the 52-week high, having risen 10.5% over 30 days and 16.9% over 90 days since the sale. At the same-ticker level, O'Day's prior 2 measurable GILD sales showed positive 90-day returns (+15.3% and +16.0%), with neither well-timed—stock rallied after both sales. This sale occurred in a period of strong upward momentum, with the company posting solid fundamentals: $7.8B in quarterly revenue, $3.1B net income, and a 6.0% annual growth rate. The transaction itself appears discretionary, not part of a disclosed trading plan, making the timing relative to recent price strength a relevant consideration for investors monitoring executive conviction.

December 2025
2025-12-30 GILEAD SCIENCES, INC. GILD
low
Sell
10,000 shares
$1,248,272
Significance 5/10

GILD CEO O'Day sells 10,000 shares at $124.83; post-sale holding 566,698 shares (-1.7%)

O'Day Daniel Patrick, Chairman & CEO, sold 10,000 shares (10.0K shares) of GILD at $124.83 on 2025-12-29 for $1,248,272.00, reducing his stake to 566,698 shares. The sale occurred near the 52-week high of $128.07 (down 3.8%), and current price is $123.18. Across O'Day's cross-ticker trading history, his 13 prior sells averaged a 90-day return of +6.0% with a 0.00% well-timed rate, indicating his prior sales were not preceded by subsequent declines; at GILD specifically, his 5 prior trades show mixed 30-day outcomes (ranging from -1.7% to +7.3%) with the one measurable 90-day result (+11.9%) being poorly-timed. This relatively modest single-transaction sale ($1.2M against a $152.8B market cap) maintains his substantial long equity position while occurring within a period of strong recent returns (90-day change +10.8%).

2025-12-01 GILEAD SCIENCES, INC. GILD
low
Sell
10,000 shares
$1,265,444
Significance 4/10

Gilead CEO O'Day sells 10,000 shares in 2 transactions for $1,265,443.77; holds 571.2K shares post-sale

Chairman & CEO Daniel Patrick O'Day executed 2 separate sales totaling 10,000 shares for $1,265,443.77 at blended average price $126.54, reducing his holdings by 1.7% to 571,203 shares. His prior trades at GILD show mixed timing outcomes: four of his most recent five GILD sales (dating 2025-08-28 through 2025-10-28) posted positive 30-day and 90-day returns, with only the August 28 sale delivering a negative 90-day return (-1.4% at 30 days, +12.2% at 90 days), indicating poorly-timed historical execution at this ticker. The current stock price of $124.33 is -2.9% from the 52-week high of $128.07 but has gained +3.8% over 30 days and +10.3% over 90 days, reflecting a continued uptrend. This sale occurs as Gilead reports strong fundamentals: $7.8B quarterly revenue, $3.1B net income, 6.0% annual revenue growth, and a 19.01 P/E ratio on a $154.3B market cap.

October 2025
2025-10-29 GILEAD SCIENCES, INC. GILD
medium
Sell
10,000 shares
$1,193,926
Significance 4/10

CEO Daniel Patrick O'Day sold 10,000 GILD shares for $1,193,925.67 on 2025-10-28; stock up 5.2% in 30 days.

Chairman & CEO Daniel Patrick O'Day executed two separate open-market sales totaling 10,000 shares (10.0K shares) for $1,193,925.67 at blended average price of $119.39, reducing his holdings by 1.7% to 581,203 shares (581.2K shares). The stock has traded well post-transaction, rising 5.2% in the 30 days following the sale, continuing a recent upward momentum with a 90-day gain of 5.5%. His prior five trades at GILD show mixed timing outcomes: two recent September sales captured 30-day gains of 5.4% and 6.3%, while historical 90-day outcomes (when measurable) showed the stock rising after his sales, indicating those exits were not well-timed for capturing downside protection. Current valuation sits at a P/E of 23.28 with the stock 4.5% below its 52-week high of $124.08, and the company reports solid fundamentals with annual revenue growth of 6.0% and $2.0B net income on $7.1B quarterly revenue.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access